Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsSharp Health Plan formulary coverage & PA update |…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentSharp-Health-PlanPolicy N/A

    Covered Prescription Drug List (4-Tier Large Group HMO/POS)

    Customize your policy alerts

    Sign up for all Sharp-Health-Plan policy alerts

    Know when Sharp-Health-Plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document lists covered outpatient prescription drugs and formulary structure for Sharp Health Plan employer-sponsored Large Group HMO and POS products that use a 4-tier formulary. It affects members and providers under the listed Large Group HMO, HDHP, and POS plan codes and custom employer groups.

    Policy Summary
    PayerSharp-Health-Plan
    PolicyCovered Prescription Drug List (4-Tier Large Group HMO/POS)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateApril 01, 2026
    Last ReviewApr 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and submit required clinical documentation when a drug is marked PA or PA** to secure coverage within the 72-hour (non-urgent) or 24-hour (urgent) decision timeframe.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4 Tierformulary tiers
    Large Group HMO & POSplan types covered
    Electronic listavailability
    04/01/2026last updated
    7-dayopioid IR threshold
    30-dayopioid ER threshold

    Coverage Criteria and Product-Level Controls

    Pharmacy Benefit Coverage Criteria

    Covered when ALL of the following are met

    Pharmacy Benefit Coverage: Drug is FDA-approved and covered under the outpatient prescription drug benefit and dispensed through a network retail, specialty, or mail order pharmacy unless otherwise indicated.

    See Member Handbook and medical benefit for physician‑administered drugs.

    Formulary Listing and Controls: If the drug is listed on the Formulary it is eligible for coverage subject to its assigned Drug Tier and any applicable coverage symbols (PA, PA**, ST, QL, SP, MO, OAC); requirements must be satisfied for coverage to be granted.

    Nonformulary drugs require a Formulary Exception approved per plan rules.

    Formulary coverage and exception criteria

    Coverage and exceptions follow these requirements and timelines

    Policy Summary
    PayerSharp-Health-Plan
    PolicyCovered Prescription Drug List (4-Tier Large Group HMO/POS)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateApril 01, 2026
    Last ReviewApr 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and submit required clinical documentation when a drug is marked PA or PA** to secure coverage within the 72-hour (non-urgent) or 24-hour (urgent) decision timeframe.
    SourceLink
    On This Page
    Coverage Criteria and Product-Level ControlsFormulary Listings, Codes, and Key ValuesPrior Authorization, Step Therapy, and Documentation RequirementsInitial and Start-of-Therapy RequirementsContinuation and Ongoing Therapy RulesStep Therapy Rules and GroupsQuantity Limits and Supply RulesDispensing Sites and Specialty Pharmacy RoutingFormulary Terms and AbbreviationsPolicy Background and Scope
    Formulary drug coverage: Drug is covered when it is on the Formulary and any applicable symbol requirements (PA, PA**, ST, QL, SP, MO, OAC) are satisfied.

    See Formulary symbols and definitions.

    Prior Authorization required: If a drug is marked PA or PA**, a completed Prior Authorization with required clinical information must be approved (72 hours for non-urgent requests; 24 hours for urgent/exigent requests) before coverage is granted.72/24 hours

    PA** applies if Step Therapy is not met; Step Therapy Exception requests follow same timelines.

    Step Therapy: For drugs marked ST, the member must meet the specified step requirements (trial/failure of preferred alternatives) unless a Step Therapy Exception is approved; exceptions require clinical justification and follow PA timelines.

    Members transitioning from another plan who are already taking the medication are not required to re‑meet Step Therapy for continuity of care.

    Quantity Limits: Drugs with QL are limited to specified quantities per prescription/time period; Prior Authorization with medical necessity documentation is required for quantities exceeding the QL.

    Decisions follow PA timelines.

    Formulary Exceptions and Nonformulary Drugs: Nonformulary drugs are not covered unless a Formulary Exception is approved; Exception requests are decided within 72 hours (non-urgent) or 24 hours (urgent/exigent) after receipt of required information and may be appealed if denied.72/24 hours

    If approved, Nonformulary coverage is subject to designated cost share tier as stated in Formulary guidance.

    Initial Coverage Criteria (Opioid ER group)

    Covered when ANY of the following are met

    ER or IR prior use: Member has filled a cumulative 7‑day or greater supply of an immediate‑release opioid agent within the past 90 days OR has been receiving an extended‑release opioid agent for a cumulative 30 days or greater within the past 90 days.7‑day IR OR 30‑day ER

    Applies to Step Therapy Group OPIOID ER 2219‑M; documentation of prior fills (dates, agent, days' supply) required for PA/step determinations.

    Short-term IR Coverage (Opioid IR combo group)

    Covered under limited circumstance

    Short‑term IR coverage: Coverage provided for up to a 7‑day supply of immediate‑release opioids if the member does not have at least a cumulative 7‑day supply of an opioid (immediate‑ or extended‑release) within the past 90 days.<=7‑day supply

    Applies to Step Therapy Group OPIOID IR COMBO PRODUCTS 1358‑E; prescriber should document lack of recent opioid exposure.

    Opioid ER - Initial Coverage Criteria

    Covered when meeting the step therapy definitions for the opioid groups

    Opioid ER approval logic: Coverage for opioid extended‑release products provided if member meets step therapy: cumulative >=7 days immediate‑release opioid in past 90 days OR cumulative >=30 days extended‑release opioid in past 90 days.IR >=7 days in 90d OR ER >=30 days in 90d

    See Step Therapy Group OPIOID ER 2219‑M for applicable products; prior authorization required where indicated.

    Opioid IR Combo - Short Supply Exception

    Coverage allowance for short-term IR opioids

    Opioid IR combo allowance: Opioid IR combo products are allowed for up to a 7‑day supply when the member lacks a cumulative 7‑day opioid supply (IR or ER) in the past 90 days.No cumulative opioid >=7 days in 90d

    Applies to Step Therapy Group OPIOID IR COMBO PRODUCTS 1358‑E; prescriber documentation of prior fills is required for PA determinations.

    Amphetamines / Anorexiants / Anti-obesity - Coverage Criteria

    Coverage for amphetamine-class stimulants, anorexiants, and select anti-obesity agents is subject to prior authorization and quantity limits.

    Amphetamine-class products: Most listed amphetamine/dextroamphetamine products require Prior Authorization and are subject to specified Quantity Limits (examples include 360 tabs every 75 days, 180 tabs every 75 days, 90 tabs every 75 days, or mL limits for oral solutions).See product‑specific QL values

    Many products require PA for members age >= 19; prescriber must provide age and justification when requesting PA that exceeds QL.

    PA and quantity limit requirements

    Coverage requirements and limits as stated per product (PA, QL, MO, SP where indicated).

    Products with PA: Many amphetamine/ADHD and related agents listed require Prior Authorization (coverage column = PA) and have product‑specific Quantity Limits and age‑based PA triggers.

    Refer to individual product entries for exact QL and age thresholds (PA required for age >= 19 for many agents).

    Stimulant (methylphenidate) coverage

    Coverage rules and limits applied to listed stimulant products

    Methylphenidate ER/OSM/patch coverage controls: Methylphenidate extended‑release formulations and patches are assigned tiers and require Prior Authorization with specified Quantity Limits; PA is required for members age >= 19.age >= 19 for PA; QL as specified per product

    Examples include 270 tabs/75 days, 180 tabs/75 days, 90 tabs/75 days depending on strength/formulation.

    Allergenic extracts/biologicals

    Allergenic extracts/biologicals and related coverage controls

    Allergen immunotherapy coverage controls: Brand allergenic extracts (e.g., Grastek, Odactra, Oralair, Ragwitek) are listed with Drug Tier 2 and require Prior Authorization and often MO as indicated.PA required

    Specific clinical PA criteria not provided in this excerpt; follow PA submission process.

    Oral immunomodulators

    Specialty/immunomodulatory oral agents

    Oral immunomodulators (RINVOQ / XELJANZ / OTEZLA): Selected oral immunomodulators (e.g., upadacitinib, tofacitinib, apremilast) are designated Specialty (SP), require Prior Authorization (PA), and have Quantity Limits (QL) as listed.QL per product

    Preferred indications are noted in product entries; fill via specialty pharmacy and follow PA documentation requirements.

    Analgesics/NSAIDs

    Analgesics and NSAIDs

    NSAIDs and analgesics coverage: Many generic NSAIDs and analgesics are Tier 1 and may carry MO (medical override) or QL; certain analgesic combinations (butalbital) have specific QLs (e.g., 48 tabs every 25 days).QL where specified; MO for many NSAIDs

    Aspirin 81 mg has QL 100 tabs every 30 days with $0 copay for members capable of pregnancy aged 12‑59 at risk for preeclampsia; otherwise not covered.

    General product-level coverage criteria

    Coverage is contingent on the following product-specific controls and age rules

    Authorization and limits apply: Many products require Prior Authorization (PA or PA**), Step Therapy (ST) for certain formulations, and have Quantity Limits (QL) typically measured per 25 days for liquid/tablet formulations or per 75 days for stimulant QLs.

    See specific product entries for exact QL and PA/ST status.

    Initial‑fill restriction: Subject to initial 7‑day limit for adults; if age 19 or younger, subject to initial 3‑day limit for many opioid liquids and tablets.7‑day adult / 3‑day <=19

    Applies to codeine, hydromorphone, morphine, tramadol and other opioid products as specified.

    Age‑based exclusions: Some opioid and combination products are not available under age 12 (e.g., certain tramadol formulations and acetaminophen‑codeine products).<12

    See product entries for exact age restrictions.

    High‑strength requirement: High‑strength patches, ER tablets or large‑mg presentations require Prior Authorization (explicitly noted as 'High Strength Requires PA').high strength per product

    Examples include fentanyl patches and high‑mg hydrocodone or morphine ER formulations.

    Formulary-specific coverage entries (examples)

    Coverage depends on drug/formulation-specific controls shown (PA, ST, QL, MO, age/initial-fill limits). Example entries:

    Tramadol examples: Tramadol oral solution 5 mg/mL and tramadol 50 mg tablets are Tier 1; require PA and have QL (1800 mL every 25 days for solution; 180 tabs every 25 days for 50 mg) with an initial 7‑day limit and initial 3‑day limit if age 19 or younger; not available under age 12.QL and age limits

    Applies per product entries.

    Acetaminophen/codeine examples: Acetaminophen‑codeine formulations list ST or PA**, QL (e.g., 2700 mL/25 days for solution; 360 tabs/25 days for certain tablet strengths), initial 7‑day limit (3‑day if age 19 or younger), and are not available under age 12 for some presentations.QL and age limits

    See specific product rows for details.

    Hydrocodone combinations: Hydrocodone/acetaminophen and hydrocodone/ibuprofen products have PA/ST and QL entries (examples: 2700 mL/25 days; 240 tabs/25 days; 180 tabs/25 days) and initial‑fill limits as specified.QL and age limits

    Refer to product table for exact strength‑based rules.

    Oxycodone combination examples: Oxycodone/acetaminophen products include ST, QL (e.g., 360 tabs every 25 days, 180 tabs every 25 days) and PA** with initial‑fill limits; pediatric initial limits apply as noted.QL and age limits

    See product entries for PA** and QL values.

    Buprenorphine buccal films (BELBUCA): BELBUCA formulations are ST and QL (60 films every 25 days) with PA** for many strengths; higher strengths require PA (High Strength Requires PA).QL and PA for high strength

    Apply step therapy where indicated.

    Formulary coverage flags

    Coverage and restrictions are indicated per drug entry as tier and coverage requirement flags.

    Formulary flags: Drugs are assigned a Drug Tier and may carry coverage requirement flags: PA (prior authorization), PA** (PA if ST not met), ST (step therapy), QL (quantity limit), SP (specialty pharmacy), MO (mail order/maintenance), OAC (oral anti‑cancer copay cap).

    Coverage contingent on satisfying the indicated flags and any numeric limits.

    General formulary coverage with quantity limits

    Coverage applies according to listed drug tier and specified coverage requirements and limits.

    Formulary coverage conditions: Drug is covered subject to its assigned Drug Tier and any listed Coverage Requirements and Limits (e.g., QL, MO); prescriptions must conform to the numeric QLs and authorization processes shown for each product.see product‑specific QL entries

    No additional diagnostic clinical criteria present in this fragment; follow PA/ST processes when required.

    Formulary coverage and quantity limits (partial)

    Drugs are covered according to assigned tier and coverage requirement codes; quantity limits apply when specified.

    General formulary rule: Coverage follows Drug Tier assignment and Coverage Requirement codes (MO, QL, PA) as listed per product; prior authorization is required where indicated by PA/PA** and MO flags imply managed coverage processes.see product‑specific QLs

    Specific clinical prior authorization criteria are detailed in payer PA guidance, not in this excerpt.

    Formulary listings and requirement codes

    Drugs are listed by therapeutic class with assigned drug tier and coverage requirement codes; coverage is conditional per the codes (e.g., MO, PA, SP, QL).

    Formulary listing and codes: Each listed drug row includes a Drug Tier and Coverage Requirements value (e.g., MO, PA, QL). For select products (e.g., zuranolone) SP, PA, and QL apply with specific numeric QLs per strength.

    No additional clinical criteria included in this fragment; follow product row and PA guidance.

    Administrative coverage flags (PA, MO)

    Coverage indicated when product-specific administrative flags are satisfied

    PA flag: Prior authorization is required for specified incretin‑mimetic agents (e.g., Mounjaro, Ozempic, Rybelsus, Trulicity) and other drugs marked 'PA' before coverage is approved.

    Prescriber must submit PA with supporting clinical documentation per plan timelines.

    MO flag: Products listing 'MO' indicate maintenance/managed coverage requiring adherence to mail‑order or management processes; documentation or formulary conditions must be met for coverage.

    Details of MO criteria are not specified in these chunks.

    This Formulary is the current official list of covered outpatient prescription drugs for Sharp Health Plan. All previous versions are no longer in effect and the document is subject to change; updates to coverage, formulary placement, or utilization controls may occur and will supersede prior versions.

    Drugs covered under the outpatient prescription drug benefit are generally dispensed through network retail, specialty, or mail-order pharmacies. Medical Benefit drugs (for example, physician‑administered or certain self‑injectable therapies) are covered under the Medical Benefit and are not processed through the outpatient prescription drug Formulary; see the Member Handbook for specific benefit and cost‑share information.

    Drugs prescribed solely for cosmetic indications are not covered. Examples of exclusions include medications prescribed exclusively for cosmetic services, hair loss, sexual dysfunction, athletic performance enhancement, and anti‑aging for cosmetic purposes. Coverage for mental performance agents is limited to medically necessary treatment of diagnosed mental illness or conditions such as dementia.

    When a generic equivalent is available, the brand‑name product is not covered unless prior authorization documents medical necessity to dispense the brand. Similarly, pharmacies may be required to dispense an interchangeable biologic unless prior authorization approves use of the reference product.

    Aspirin 81 mg is generally not covered under the outpatient prescription benefit, except for members capable of pregnancy aged 12–59 years at risk for preeclampsia, for whom a $0 copay applies.

    Certain opioid and combination products carry pediatric restrictions. Specifically, selected tramadol formulations and some acetaminophen‑with‑codeine products are not available under age 12; many opioid liquid/tablet entries also include initial short‑fill rules and pediatric initial‑fill limits.

    Some RELION‑branded insulin products are explicitly listed as not covered (noted in proximity to Novolin and related insulin entries); covered insulin products are listed with their coverage requirement flags (e.g., MO) and tier assignments.

    Formulary Listings, Codes, and Key Values

    Formulary drug listings (by therapeutic class)mixed
    N/AAlphabetical lists and therapeutic categories shown; specific billing codes not present in this excerpt
    Step Therapy Group - Opioid ERmixed
    2219-MOPIOID ER group identifier
    Step Therapy Group - Opioid IR Combomixed
    1358-EOPIOID IR COMBO PRODUCTS group identifier
    Step Therapy Groupsmixed
    OPIOID ER 2219-MStep Therapy Group name
    OPIOID IR COMBO PRODUCTS 1358-EStep Therapy Group name
    Listed Drugs and Limitsmixed
    phentermine hcl-topiramate cap er 24hr 3.75-23 mglisted product; COVERAGE REQUIREMENTS AND LIMITS = PA; generic
    phentermine hcl-topiramate cap er 24hr 7.5-46 mglisted product; DRUG TIER = 1; COVERAGE REQUIREMENTS AND LIMITS = PA; generic
    phentermine hcl-topiramate cap er 24hr 11.25-69 mglisted product; DRUG TIER = 1; COVERAGE REQUIREMENTS AND LIMITS = PA; generic
    phentermine hcl-topiramate cap er 24hr 15-92 mglisted product; DRUG TIER = 1; COVERAGE REQUIREMENTS AND LIMITS = PA; generic
    QSYMIA CAP 3.75-23brand (phentermine/topiramate); DRUG TIER = 2; COVERAGE REQUIREMENTS AND LIMITS = PA
    QSYMIA CAP 7.5-46MGbrand; DRUG TIER = 2; COVERAGE REQUIREMENTS AND LIMITS = PA
    QSYMIA CAP 11.25-69brand; DRUG TIER = 2; COVERAGE REQUIREMENTS AND LIMITS = PA
    QSYMIA CAP 15-92MGbrand; DRUG TIER = 2; COVERAGE REQUIREMENTS AND LIMITS = PA
    orlistat cap 120 mggeneric; DRUG TIER = 1; COVERAGE REQUIREMENTS AND LIMITS = PA
    WEGOVY TAB 1.5MGbrand semaglutide (weight management); DRUG TIER = 2; COVERAGE REQUIREMENTS AND LIMITS = PA
    1–10 of 20
    1/2
    Analgesic combinations (butalbital, aspirin, acetaminophen)mixed
    Butalbital-Acetaminophen 50-325 mgButalbital-acetaminophen tab 50-325 mg — QL (48 tabs every 25 days)
    Butalbital-Acetaminophen-Caffeine 50-325-40 mgButalbital-acetaminophen-caffeine tab 50-325-40 mg — QL (48 tabs every 25 days)
    Butalbital-Aspirin-Caffeine 50-325-40 mgButalbital-aspirin-caffeine cap 50-325-40 mg — QL (48 caps every 25 days)
    Selected opioid products (short-acting and patches)mixed
    Codeine sulfate 30 mgCodeine sulfate tab 30 mg — PA, QL (42 tabs every 25 days); Subject to initial 7-day limit; age 19 or younger subject to initial 3-day limit
    Fentanyl TD patch 12-100 mcg/hrFentanyl td patch 72hr (12,25,37.5,50,62.5,75,87.5,100 mcg/hr) — ST or PA; QL (10 patches every 25 days); High strength requires PA
    Opioid analgesics and combinationsmixed
    Hydrocodone ER/24hr & cap ER 12hrMultiple strengths (10–120 mg) — ST or PA; QL commonly 30–60 caps/tabs every 25 days; high strength requires PA
    Hydromorphone (liquid/tablet/ER)Hydromorphone forms — PA, QL (various: 600 mL, 180,150,60 tabs every 25 days); initial 7-day limit; age <20 initial 3-day limit
    Meperidine 50 mgMeperidine oral solution and tablets — PA, QL (90 mL or 18 tabs every 25 days); initial 7-day limit; age <20 initial 3-day limit
    Methadone (various forms)Methadone concentrations/tablets — QL (30 mL every 25 days) indicated for opioid addiction; some formulations ST and PA with larger QLs
    Morphine sulfate (IR/ER/soln/caps)Many formulations and strengths — mix of ST and PA; QL examples: caps/tabs 30 caps/25 days or liquid volumes; high strength requires PA
    Oxycodone (IR/solution)Oxycodone tabs and solutions — PA, QL (e.g., 180 caps or 90 mL every 25 days); initial 7-day/3-day age limits
    Oxymorphone 5-10 mgOxymorphone tabs — PA, QL (90–180 tabs every 25 days); initial 7-day/3-day age limits
    Tapentadol 50-100 mgTapentadol tabs — PA required
    Tramadol (IR/ER/oral soln)Tramadol solutions and tablets — PA and QL (e.g., 1800 mL or 180 tabs every 25 days); many ER formulations ST or PA; Not available under age 12
    Acetaminophen w/ codeine (various)Acetaminophen w/ codeine solutions and tablets — ST, QL (e.g., 2700 mL or 400 tabs every 25 days); PA**; initial 7-day limit; not available under age 12
    N/Amixed
    No codes listed
    No billing codes in excerptmixed
    N/ANo CPT/HCPCS/ICD/NDC codes listed in this excerpt; only drug names, tiers, and coverage flags are present.
    Formulary coverage codes and limitsmixed
    QLQuantity limit (examples provided inline)
    MOCoverage requirement code (used for many listed products)
    Formulary requirement codes used in this segmentmixed
    MOCoverage requirement code (document lists MO for many generic and brand products)
    SPSpecialty pharmacy requirement (appears for zuranolone)
    PAPrior authorization requirement (appears for zuranolone)
    QLQuantity limit (appears for zuranolone; specific limits provided)
    Selected listed drugs and tiers (section start)mixed
    trimipramine maleate cap 100 mgDRUG TIER = 1; COVERAGE REQUIREMENTS AND LIMITS = MO
    acarbose tab 25 mgDRUG TIER = 1; COVERAGE REQUIREMENTS AND LIMITS = MO
    acarbose tab 50 mgDRUG TIER = 1; COVERAGE REQUIREMENTS AND LIMITS = MO
    acarbose tab 100 mgDRUG TIER = 1; COVERAGE REQUIREMENTS AND LIMITS = MO
    Antidiabetic combinations (sample)mixed
    GLYXAMBI TAB 10-5 MGDRUG TIER = 2; COVERAGE REQUIREMENTS AND LIMITS = MO
    GLYXAMBI TAB 25-5 MGDRUG TIER = 2; COVERAGE REQUIREMENTS AND LIMITS = MO
    SYNJARDY TAB and XR formulationsDRUG TIER = 2; COVERAGE REQUIREMENTS AND LIMITS = MO
    Biguanides and rescue glucagon productsmixed
    metformin hcl tabs and ER formulationsDRUG TIER = 1; COVERAGE REQUIREMENTS AND LIMITS = MO
    BAQSIMI ONE POW 3MG/DOSEDRUG TIER = 2
    glucagon for inj 1 mgDRUG TIER = 1
    Coverage requirement symbols
    Oral Anti-Cancer (OAC) copay capCopayments/coinsurance not to exceed $250 for an individual prescription of up to a 30-day supply
    PA (Prior Authorization)Requires prior authorization by Sharp Health Plan based on specific clinical criteria; PA** applies if Step Therapy is not met
    QL (Quantity Limit)Coverage limited to a specific quantity per prescription and/or time period; prior authorization required for quantities exceeding the limit
    ST (Step Therapy)Coverage depends on previous use of another drug; prior authorization may be required
    SP (Specialty)Specialty drugs must be filled by Sharp Health Plan Specialty Pharmacy network and are limited to a 30-day supply per fill
    Opioid step therapy thresholds
    Immediate‑release opioid cumulative supply threshold>= 7 days cumulative supply within the past 90 days (required for Opioid ER group coverage)
    Extended‑release opioid cumulative supply threshold>= 30 days cumulative supply within the past 90 days (alternative criterion for Opioid ER group coverage)
    Opioid IR combo short‑supply allowanceCoverage up to a 7‑day supply if member does not have at least a cumulative 7‑day opioid supply in the past 90 days
    Opioid prior‑use definitions
    Extended‑release opioid prior exposureCumulative 30 days or greater within the past 90 days (counts toward Opioid ER step requirement)
    Immediate‑release opioid prior exposureCumulative 7 days or greater within the past 90 days (counts toward Opioid ER step requirement)
    Documentation requiredDocumentation of prior opioid fills (dates, agent, days supply) to demonstrate fulfillment of step therapy criteria
    Example quantity limits
    Example quantity limits — caps/tabsExamples include 90 caps every 75 days; 180 caps every 75 days; 540 tabs every 75 days
    Example quantity limits — oral solutionExamples include 5400 mL every 75 days; other solution limits shown per product (e.g., 2700 mL, 3600 mL)
    Most QLs expressed per intervalMany quantity limits are expressed per 25 or 75 day intervals depending on product (see product entry)
    Age‑based PA and representative QLs
    Age threshold for PA on many amphetamine/ADHD productsPrior authorization is required for members aged greater than or equal to 19 for multiple products (PA required for age >= 19)
    AZSTARYS and dexmethylphenidate QLAZSTARYS: QL 90 caps every 75 days; many dexmethylphenidate formulations have QLs (90–180–360 caps/tabs per 75 days) and PA for age >= 19
    Atomoxetine QLsAtomoxetine strengths have QLs such as 360 caps every 75 days; 180 caps every 75 days; 90 caps every 75 days depending on strength
    Methylphenidate PA and quantity examples
    Methylphenidate ER/OSM/patch PA rulePrior authorization required for many methylphenidate extended‑release and osmotic‑release formulations and transdermal patches; PA is required for members aged >= 19
    Representative methylphenidate QLsExamples include 270 tabs every 75 days (some ER tabs), 180 tabs every 75 days (some OSM strengths), and 90 tabs every 75 days for higher‑strength products
    Initial‑fill limits for opioids apply to some stimulant entriesFormulary includes initial‑fill concepts elsewhere (standard initial 7‑day limit; 3‑day if age 19 or younger) that may apply to controlled substances
    QL interval conventions and initial‑fill limits
    Most QLs per 25‑day intervalsMany quantity limits in the formulary are expressed per 25 days (e.g., 48 tabs/25 days; 900 mL/25 days; 180 tabs/25 days)
    Initial short‑fill limitsStandard initial 7‑day limit applies; initial 3‑day limit applies if age 19 or younger for many opioid liquids and tablets
    Quantity limits examples across classesFurther examples include 180 tabs every 25 days; 2700 mL every 25 days; 360 tabs every 25 days depending on product

    Prior Authorization, Step Therapy, and Documentation Requirements

    Note

    Formulary includes PA, QL, ST and related controls

    The formulary includes coverage controls (PA, PA**, QL, ST, SP, MO). Refer to the Step Therapy and Prior Authorization sections of the Formulary for specific requirements for each drug.

    • Symbols: PA = Prior Authorization; PA** = PA if Step Therapy not met; QL = Quantity Limit; ST = Step Therapy; SP = Specialty Pharmacy; MO = Mail Order (90-day)
    Prior Authorization

    Obtain Prior Authorization for PA‑designated drugs

    Drugs marked 'PA' in the Coverage Requirements and Limits column require a prior authorization submitted by the Prescribing Provider; approvals are based on Sharp Health Plan clinical criteria and follow PA timelines (72 hours non‑urgent; 24 hours urgent/exigent).

    • Submit PA by phone, fax, or electronic Prior Authorization form.
    • If denied, member/provider may file an appeal as described in the Formulary.
    Prior Authorization

    PA and PA** require PA submission (PA** when ST unmet)

    Drugs listed with 'PA' or 'PA**' require prior authorization; PA** indicates PA is required when Step Therapy has not been met and may be requested to bypass ST when medically necessary.

    • PA** is Prior Authorization if Step Therapy not met; submit clinical justification to request bypass.
    Prior Authorization

    Meet step therapy tied to opioid Step Therapy Group IDs

    Opioid products in Step Therapy Group OPIOID ER (2219‑M) and OPIOID IR COMBO (1358‑E) are subject to step therapy; coverage requires meeting the group criteria tied to those Step Therapy Group IDs.

    • Check Step Therapy Group identifiers: OPIOID ER = 2219‑M; OPIOID IR COMBO = 1358‑E.
    Documentation Required

    Opioid ER: document cumulative IR/ER prior exposure

    For Opioid ER group (OPIOID ER 2219‑M) prior authorization/coverage requires prior opioid exposure: a cumulative ≥7‑day supply of an immediate‑release opioid in the past 90 days OR cumulative ≥30 days of an extended‑release opioid in the past 90 days.

    • Document prior fills to show either: cumulative ≥7 days IR in 90 days, or cumulative ≥30 days ER in 90 days.
    Step Therapy

    Opioid IR combo: allow up to 7‑day IR supply when no recent exposure

    Opioid IR combo group (OPIOID IR COMBO PRODUCTS 1358‑E) allows coverage of up to a 7‑day supply of immediate‑release opioids if the member does not have at least a cumulative 7‑day opioid supply (IR or ER) within the past 90 days.

    • Coverage limited to ≤7 days when no prior cumulative ≥7‑day opioid supply in prior 90 days.
    Prior Authorization

    Obtain PA and adhere to QLs for amphetamine‑class products

    Many amphetamine‑class stimulants and related anorexiant/anti‑obesity agents require prior authorization and have quantity limits; providers must request PA and follow QL limits noted for each product.

    • QL examples: 360 tabs/75 days, 180 tabs/75 days, 90 tabs/75 days, or mL limits for oral solutions.
    • PA is required for patients age ≥19 for many listed products.
    Prior Authorization

    Obtain PA where formulary shows 'PA' for ADHD/related agents

    Multiple ADHD/amphetamine‑class products show 'Coverage Requirements and Limits = PA'; providers must obtain prior authorization where PA is indicated before coverage is granted.

    • Confirm product‑specific QL and age‑based PA (PA required for age ≥19) when submitting PA.
    Prior Authorization

    PA required for methylphenidate ER/patch in adults (age ≥19)

    Methylphenidate extended‑release products and transdermal patch formulations require prior authorization and have specified quantity limits; PA is specifically required for members age ≥19 for listed methylphenidate ER/OSM/patch entries.

    • QL examples for methylphenidate ER: 270, 180, or 90 tabs per 75 days depending on strength.
    • Include age verification when requesting PA for age ≥19.
    Billing Rule

    Route selected specialty immunomodulators via Specialty Pharmacy with PA and QL

    Select specialty immunomodulators (e.g., upadacitinib, tofacitinib, apremilast) require prior authorization and must be routed via the specialty pharmacy; quantity limits apply per product.

    • These agents are flagged SP and PA; QLs shown (e.g., upadacitinib QL 12 mL every 1 day; Otezla QL 55 or 41 tabs per interval).
    Prior Authorization

    Obtain PA for opioid products (high‑strength require PA)

    Many opioid formulations are designated PA or PA**; high‑strength formulations explicitly require prior authorization—obtain PA before dispensing to avoid denial.

    • High‑strength patches/tables (e.g., fentanyl ≥50 mcg/hr, hydrocodone ER high mg) require PA.
    • PA** may apply for ER/ER products when ST not met.
    Step Therapy

    Follow PA/ST and initial‑fill rules for opioid and buprenorphine products

    Numerous opioid and buprenorphine products require prior authorization or step therapy; providers must follow PA/ST flags and initial‑fill limits where specified.

    • Many products are ST or PA**; initial 7‑day limit applies (3‑day if age ≤19) for many liquids/tablets.
    • Buprenorphine buccal films may be ST with QL (e.g., BELBUCA 60 films/25 days) and PA**.
    Prior Authorization

    Obtain PA (and satisfy MO) for selected topical/hormonal products

    Several topical and hormonal androgen/testosterone products are listed with 'PA, MO' coverage requirements; providers must obtain prior authorization and follow any MO processes required by the plan.

    • Examples: METHITEST, NATESTO gel and testosterone topical gels list PA and MO.
    Billing Rule

    Follow MO and QL codes; do not exceed listed quantity limits

    Products marked with MO or QL carry managed coverage or quantity limits; prescribers should follow the MO process if applicable and ensure prescriptions do not exceed listed QLs.

    • MO entries may require medical/other authorization per plan practice.
    • Claims may be denied if QLs (e.g., inhaler or mL limits) are exceeded.
    Billing Rule

    Comply with MO/QL coverage codes when present

    Coverage requirement codes (MO, QL) indicate that prescribers must meet the plan's managed‑coverage or quantity‑limit processes; prior authorization may be required where MO is indicated.

    • MO often denotes coverage requirements or medical override pathways; follow instructions in Formulary.
    • Submit PA with supporting documentation if MO/PA noted.
    Prior Authorization

    Oxtellar XR entries may require PA/MO prior to coverage

    Some branded extended‑release oxcarbazepine (Oxtellar XR) entries are shown with DRUG TIER = 2 and coverage requirement 'MO', implying prior authorization/management oversight may be required for coverage.

    • Confirm MO/PA requirements for Oxtellar XR strengths (150/300/600 mg) when submitting authorization.
    Prior Authorization

    PA and Specialty Pharmacy routing required for ZURZUVAE (zuranolone)

    Certain products (e.g., ZURZUVAE/zuranolone) require prior authorization and must be routed through specialty pharmacy; PA and QL enforcement apply for listed strengths.

    • ZURZUVAE is flagged SP, PA, QL — QL: 2 caps/day for 20/25 mg; 1 cap/day for 30 mg.
    • Submit PA and route via Sharp Health Plan specialty network (CVS Specialty) per site‑of‑care rules.
    Prior Authorization

    Obtain PA for selected incretin‑mimetic agents

    Several incretin‑mimetic agents (Mounjaro, Ozempic, Rybelsus, Trulicity) are designated 'PA' (some also 'MO'); prescribers must obtain prior authorization for these agents before coverage.

    • Mounjaro, Ozempic, Rybelsus and Trulicity list PA; some strengths also show MO.
    • Include required clinical documentation with PA submission.
    Note

    Step Therapy section applies to multiple classes

    The Formulary includes a Step Therapy Criteria section; drugs marked 'ST' require step adherence and providers should consult the Step Therapy Criteria for class‑specific step rules.

    • Step Therapy exceptions may be requested via the Prior Authorization process with clinical justification.
    Step Therapy

    Require and document trials for Step Therapy; submit exceptions via PA

    Sharp Health Plan may require trials of specified drugs (Step Therapy) before covering higher‑step agents; providers may submit Step Therapy Exception requests with clinical justification via the PA process.

    • If ST exception is requested, decision timelines follow PA timelines (72 hours non‑urgent; 24 hours urgent/exigent).
    Prior Authorization

    Submit Step Therapy Exceptions via Prior Authorization with clinical justification

    Providers may submit a Step Therapy Exception with clinical justification through the Prior Authorization process; Step Therapy Exception requests follow PA decision timelines (72 hours non‑urgent; 24 hours urgent/exigent).

    • If Plan fails to respond within timelines, a completed request is deemed granted.
    • Include clinical rationale and supporting documentation with the exception request.
    Documentation Required

    Ensure member meets supply‑history thresholds under Step Therapy

    Members must meet the Step Therapy supply‑history thresholds for coverage; prescribers should document prior fills and supply to demonstrate step fulfillment as defined in the Step Therapy Criteria.

    • Opioid thresholds: cumulative ≥7 days IR in past 90 days or cumulative ≥30 days ER in past 90 days.
    • For IR combo, document absence of prior cumulative ≥7‑day opioid supply to support a ≤7‑day allowance.
    Documentation Required

    Document prior opioid exposure per opioid step therapy rules

    Coverage for many opioid ER/IR agents is contingent on prior short‑term IR opioid exposure or prior ER opioid use as specified by the opioid step therapy group rules; document prior opioid use accordingly.

    • Document dates, agent names, and days' supply of prior opioid fills to show step criteria fulfillment.
    Note

    When Step Therapy not specified, follow PA/MO/QL flags

    Some sections do not specify explicit Step Therapy rules in this extract; when ST is not shown, follow PA/MO/QL flags indicated for the product.

    • If ST is not listed, check Coverage Requirements column for PA, QL, MO and follow those processes.
    Documentation Required

    Submit PA with required clinical information; timelines apply

    PA requests must be submitted by the Prescribing Provider (phone/fax/electronic) with supporting clinical information; determinations are made within 72 hours for non‑urgent requests and within 24 hours for urgent/exigent requests.

    • Incomplete requests will trigger notification of needed information within 72 hours (24 hours if exigent).
    • If Sharp Health Plan fails to respond within timelines to a completed PA request, the request is deemed granted.
    Documentation Required

    Provide complete supporting documentation with PA to avoid delays

    Providers must supply all required supporting clinical information when submitting a PA; incomplete or missing information will prompt a request for additional information and can delay determinations.

    • Notification of missing info: within 72 hours (24 hours exigent).
    • Decisions issued within 72 hours (non‑urgent) or 24 hours (urgent/exigent) after receipt of all required info.
    Documentation Required

    Document cumulative opioid supply thresholds (7‑day IR or 30‑day ER within 90 days)

    For opioid step therapy, documentation must show cumulative supply thresholds: at least a cumulative 7‑day supply of IR opioid within the past 90 days or at least a cumulative 30‑day supply of ER opioid within the past 90 days.

    • Include prior fill dates, agent names, and days' supply to demonstrate the cumulative thresholds.
    Documentation Required

    Include prior opioid fill details when requesting opioid PA

    When requesting PA for opioids under step therapy, include prior opioid fill records (dates, agent, and days' supply) to demonstrate fulfillment of step criteria.

    • Records should cover the prior 90‑day period and show cumulative days' supply.
    Documentation Required

    Provide age and justification for amphetamine/anorexiant PA requests (age ≥19)

    When requesting PA for amphetamine/anorexiant products for patients age ≥19, prescribers must provide the member's age and clinical justification supporting medical necessity.

    • Age verification is required for PA (many entries state 'PA Required for age ≥19').
    • If requesting quantities above QL, supply medical necessity rationale.
    Documentation Required

    Supply medical necessity documentation for methylphenidate ER/patch PA

    Prescribers should include clinical documentation supporting medical necessity when requesting prior authorization for methylphenidate ER/OSM/patch formulations and related PA‑designated stimulant entries.

    • Include indication, prior therapies tried (if applicable), and age when member is ≥19.
    Billing Rule

    Adhere to initial‑fill limits (7‑day standard; 3‑day if age ≤19)

    Initial‑fill limits apply to many opioid products: a standard initial 7‑day limit for adults and an initial 3‑day limit for patients age 19 or younger; documentation may be required for overrides.

    • Apply initial 7‑day limit for adult initial fills; if member is ≤19, initial 3‑day limit applies.
    • Document clinical rationale if requesting override of initial‑fill limits.
    Documentation Required

    Provide PA/ST documentation per product designations

    Prior authorization documentation is required for PA‑designated products and for PA** or high‑strength designations; Step Therapy (ST) may require additional documentation for exception requests.

    • Include clinical justification, prior treatment history, and any requested quantity rationale for PA/ST decisions.
    Denial Risk

    Formulary is subject to change — verify current version

    This Formulary document is subject to change and prior versions are not in effect; providers should verify current Formulary status as coverage may change with updates.

    • Check the online electronic drug list for the most current Formulary updates (last updated 04/01/2026).
    Denial Risk

    Risk of PA denial — appeals available

    Prior Authorization requests may be denied if supporting information does not meet Sharp Health Plan clinical policies; denied requests may be appealed by the member, authorized representative, or prescribing provider.

    • If PA is denied, follow the Formulary 'You Have the Right to Appeal' instructions and timelines.
    Denial Risk

    Nonformulary coverage requires a Formulary Exception (appealable)

    Nonformulary drugs are not covered unless a Formulary Exception is approved via the Prior Authorization/Formulary Exception process; denials of exceptions can be appealed.

    • If a nonformulary drug is approved, Tier 3 cost share applies for brand‑name; Tier 1 applies for generic nonformulary approvals.
    Denial Risk

    Step Therapy non‑fulfillment may cause coverage denial

    Coverage may be denied if the member does not meet Step Therapy supply thresholds (e.g., no cumulative 7‑day IR opioid supply in past 90 days and not receiving cumulative 30‑day ER opioid use in past 90 days).

    • Verify prior opioid supply before submitting PA for opioid ER group; absence of required prior use may trigger denial.
    Denial Risk

    Opioid Step Therapy denial trigger if criteria unmet

    Requests may be denied for opioid Step Therapy groups if step criteria are not met (no recent IR opioid fill ≥7 days in past 90 days or no cumulative ER opioid use ≥30 days in past 90 days).

    • Ensure opioid step thresholds are documented in the PA to avoid denial.
    Denial Risk

    AMPHETAMINES: PA/QL denials possible if age or QL requirements not met

    Prior authorization denials for amphetamine products can occur if age requirements (PA required for age ≥19) or quantity limits are not met or supported by documentation.

    • Include age and medical justification when PA required for patients age ≥19.
    • Provide rationale when requesting quantities exceeding listed QLs.
    Denial Risk

    Claims may be denied if PA is not obtained for PA‑flagged drugs

    Coverage for products marked 'PA' may be denied if prior authorization is not obtained before dispensing; obtain PA to prevent claim denial.

    • Verify PA requirement on the Formulary entry before prescribing/dispensing.
    Denial Risk

    Methylphenidate ER/patch: PA required — risk of denial if not obtained

    Prior authorization is a trigger for methylphenidate ER/OSM/patch products; PA is required for many strengths and for members age ≥19 — failure to obtain PA risks denial.

    • Confirm PA requirement and include age/clinical justification in the PA submission.
    Denial Risk

    PA required for modafinil, allergenics and certain specialty agents

    PA is required for modafinil and listed allergenic biologics, and for select specialty agents (e.g., upadacitinib, tofacitinib, apremilast); lack of PA can lead to denial.

    • Modafinil entries show PA and MO; specialty immunomodulators show SP and PA.
    Prior Authorization

    Obtain PA for select incretin agents to avoid denial

    Prescriptions for select incretin mimetic agents (Mounjaro, Ozempic, Rybelsus, Trulicity) list 'PA' (and sometimes 'MO'); prescribers must obtain prior authorization before coverage is approved.

    • Include required clinical information when submitting PA for incretin agents.

    Initial and Start-of-Therapy Requirements

    Initial therapy requirements

    Initial coverage conditional on prior opioid exposure

    Prior IR or ER use: Member has filled a cumulative 7‑day or greater supply of an immediate‑release opioid within the past 90 days OR has been receiving an extended‑release opioid for a cumulative 30 days or greater within the past 90 days.>=7 days IR in 90d OR >=30 days ER in 90d

    Documentation of prior fills (dates, agent, days supply) required when submitting PA or Step Therapy Exception requests.

    Opioid Initial Therapy

    Opioid step therapy initial conditions

    Opioid initial therapy: Initial coverage for Opioid ER group requires prior short‑term IR opioid exposure (cumulative >=7 days in past 90 days) OR cumulative ER opioid use >=30 days in past 90 days; Opioid IR combo group allows up to a 7‑day IR supply if no recent cumulative opioid exposure in 90 days.IR >=7 days in 90d OR ER >=30 days in 90d; IR combo <=7 days if no prior >=7 days

    Applies to Step Therapy Groups OPIOID ER 2219‑M and OPIOID IR COMBO PRODUCTS 1358‑E.

    Initial therapy limits

    Initial-fill rules applied to many opioid products

    Initial‑fill limits: Many opioid liquids and tablets are subject to an initial 7‑day limit for adults; if the member is age 19 or younger, an initial 3‑day limit applies.7‑day adult / 3‑day <=19

    Applies to hydromorphone, morphine, codeine, and similar products as noted in product entries; documentation may be required for overrides.

    Initial fill constraints

    Initial fill limits and pediatric initial limits applied to many opioid products.

    Initial‑fill constraints: Opioid products commonly enforce an initial short‑fill (7‑day standard); for members age 19 or younger the initial short‑fill is 3 days. Age‑based exclusions also apply for certain products (e.g., 'Not available under age 12').7‑day adult / 3‑day <=19 / not available <12 where specified

    Providers should document age and indication when requesting PA or overrides.

    Continuation and Ongoing Therapy Rules

    Continuation and continuity of therapy

    Continuity and ongoing therapy rules

    Approved PA continuation: If a Prior Authorization is approved for a medication and condition, the Plan will not discontinue or limit coverage while the same medication is prescribed for the same condition provided it remains appropriate and safe.
    Continuity from prior insurer: Members moving from another plan who are already taking a medication will not be required to meet Step Therapy to continue that medication; providers may need to submit documentation to ensure continuity.

    Provider should submit prior insurer medication history for continuity requests.

    Step Therapy Rules and Groups

    Step Therapy TopicSummary
    Step Therapy Criteria section existsThe formulary contains a Step Therapy Criteria section that applies to multiple therapeutic classes; drugs marked 'ST' require prior trial of specified alternatives before coverage unless an approved exception is provided.
    Program purposeStep Therapy is used to encourage safe, cost‑effective medication use by requiring a 'step' approach (trial of a proven, cost‑effective drug) before covering higher‑step therapies.
    Exception processProviders may submit a Step Therapy Exception with clinical justification via the Prior Authorization process; requests must be decided within 72 hours for non‑urgent or 24 hours for exigent requests (deemed granted if not decided within those timeframes).
    RequirementWhat the Formulary Requires
    Formulary-designated Step Therapy (ST)Drugs with the ST symbol require trial of specified alternative(s) (as listed on the Formulary) before coverage of higher‑step drugs; prior authorization may be required if ST not met (PA** applies).
    Exception considerationSharp Health Plan will consider Step Therapy exceptions when the provider documents that the required step drug is inconsistent with good professional practice or when medically necessary; follow the Prior Authorization/Step Therapy Exception process.
    Continuity of careMembers who transfer from another plan and are currently taking a medication will not be required to satisfy Step Therapy to continue that medication; provider may need to submit documentation to ensure continuity of coverage.
    ActionProvider must do
    Submit Step Therapy Exception via Prior AuthorizationPrescribing provider must submit a Step Therapy Exception request through the Prior Authorization process with supporting clinical justification when the required step drug is unsuitable or medically unnecessary.
    Required documentationInclude clinical documentation demonstrating why the step drug is inconsistent with good professional practice or evidence of medical necessity to support the exception request.
    Decision timelineSharp Health Plan must make a determination on completed non‑urgent Step Therapy Exception requests within 72 hours (24 hours for exigent/urgent requests); incomplete requests will trigger a notification of needed information within those same timeframes.
    Opioid Step GroupSupply threshold for coverage
    OPIOID ER (2219-M)Member must have filled a cumulative 7‑day or greater supply of an immediate‑release opioid within the past 90 days OR have been receiving an extended‑release opioid for a cumulative 30 days or greater within the past 90 days for coverage under the Opioid ER group.
    OPIOID IR COMBO (1358-E) — short IR allowanceCoverage provided for up to a 7‑day supply of immediate‑release opioids if the member does not have at least a cumulative 7‑day supply of an opioid (IR or ER) within the past 90 days.
    Opioid GroupPrior exposure requirement / Initial fill allowance
    Opioid ER group (2219-M)Requires prior opioid exposure: cumulative ≥7 days IR within past 90 days OR cumulative ≥30 days ER within past 90 days to qualify for coverage of ER agents.
    Opioid IR combination products (1358-E)Allows up to a 7‑day supply of immediate‑release opioid if member lacks a cumulative 7‑day opioid supply in the past 90 days (short‑supply exception).
    Initial short‑fill limitsMany opioid liquids and tablets are subject to an initial 7‑day limit (initial 3‑day limit for members age 19 or younger) unless criteria for continuation are met.
    Formulation typesStep Therapy flag
    Extended‑release tablets / transdermal patches (selected)Certain ER formulations and patches (e.g., fentanyl patches, hydromorphone ER, select morphine ER/tramadol ER) are flagged ST or require failure of preferred agents prior to coverage.
    High‑strength formulationsHigh‑strength patches and ER products frequently require PA and/or are subject to ST as indicated in product entries (see specific drug listings).
    ScopeRequirement
    ST applies where listedProducts marked 'ST' in the Coverage Requirements and Limits column must follow the Step Therapy criteria (trial of specified alternatives) before coverage is granted; providers may request exceptions per the prior authorization/step therapy exception process.
    ExamplesSelected opioid combination products, certain buprenorphine/buccal films and select ER opioid formulations are shown with ST flags in the formulary entries and require step compliance prior to coverage or PA** when step not met.
    ProductRouting / Authorization
    ZURZUVAE (zuranolone) — 20 mg / 25 mg / 30 mgRequires Specialty Pharmacy (SP) routing and Prior Authorization (PA); quantity limits apply (QL: 2 caps/day for 20 mg and 25 mg; 1 cap/day for 30 mg) as listed in the formulary.
    Agent class / ExamplesRequirement
    Incretin‑mimetic agents (GLP‑1 / GIP) — examplesMultiple incretin‑mimetic agents (e.g., Mounjaro, Ozempic, Rybelsus, Trulicity) are listed with 'PA' in the Coverage Requirements and Limits column; prior authorization is required before coverage.
    Example (brand vs generic)Implication
    BRIVIACT (brand) vs brivaracetam (generic)Brand BRIVIACT entries are assigned to a higher drug tier (tier 2) while generic brivaracetam products are tier 1; tiering suggests preference for generics first which may act as a step before covering higher‑tier brand formulations.
    Product (Xcopri / Xcopri packaging)Formulary note
    Xcopri (cenobamate) — multiple pack sizes and tablet strengthsCenobamate products (Xcopri) are listed at drug tier 2 with 'MO' indicated for many formulations, signifying utilization management oversight; while MO is shown, explicit step‑therapy algorithms are not detailed in the excerpt but utilization management is implied.

    Quantity Limits and Supply Rules

    Quantity limit (formulary QL symbol)
    Formulary QL symbol meaningQuantity Limit (QL) — coverage limited to a specific quantity per prescription and/or time period as indicated per drug
    Maintenance drugs (MO)Maintenance drugs designated MO are eligible for up to a 90‑day supply via mail order
    EnforcementPrior authorization required for quantities exceeding the QL; PA decisions follow 72‑hour non‑urgent / 24‑hour urgent timeframes
    Maintenance and mail‑order (MO) eligibility
    90‑day mail order eligibilityMaintenance and other QL‑designated drugs are eligible for 90‑day supply via mail order (MO) where indicated
    Specialty suppliesSpecialty drugs (SP) remain limited to 30‑day supply per fill and must be dispensed via specialty pharmacy
    Where notedMO and SP flags appear in the Coverage Requirements and Limits column for applicable products
    Amphetamine/dextroamphetamine quantity limits
    Amphetamine/dextroamphetamine QL examplesExamples include 360 tabs every 75 days; 270 caps every 75 days; 180 caps every 75 days; 90 caps every 75 days depending on strength/formulation
    Age/PA notePA required for age >=19 for many strengths; MO often indicated for maintenance fills
    Formulations coveredIncludes multi‑strength ER caps, 3‑bead ER caps, and IR tabs/solutions
    Lisdexamfetamine and phentermine‑topiramate QLs
    Lisdexamfetamine & phentermine‑topiramate QLsExamples: 180 caps every 75 days; 90 caps every 75 days depending on strength
    PA requirementCoverage requires prior authorization as indicated in formulary entries
    TieringSome brand formulations (e.g., QSYMIA) are tiered and subject to PA
    Atomoxetine quantity limits
    Atomoxetine QL examples360 caps every 75 days; 180 caps every 75 days; 90 caps every 75 days (varies by strength)
    Age/PA notePA required for age >=19 for atomoxetine strengths shown
    MO flagMany atomoxetine entries also list MO (maintenance) where applicable
    QELBREE (viloxazine) quantity limit
    QELBREE (viloxazine) QL270 caps every 75 days
    MO noteFormulary indicates MO for maintenance where applicable
    ApplicabilityApplies to listed QELBREE strengths in the formulary entries
    WAKIX (pitolisant) quantity limit
    WAKIX (pitolisant) QL2 tablets every 1 day
    Coverage requirementsWAKIX entries show SP and PA in addition to the per‑day QL
    TieringWAKIX is listed as a specialty tier drug in the formulary entries
    AZSTARYS quantity limit
    AZSTARYS QL90 caps every 75 days
    PA and agePA required for age >=19; MO indicated for maintenance fills
    Strength coverageApplies to listed AZSTARYS strengths shown in formulary
    Dexmethylphenidate / methylphenidate quantity limits
    Dexmethylphenidate / methylphenidate QLsMultiple examples across strengths: 360/270/180/90/540 tabs or caps every 75 days; solution mL limits (e.g., 5400 mL) also listed
    PA & age rulePA required for age >=19 for many strengths; QL varies by strength and formulation
    Formulation examplesER caps, chewable tabs, osmotic OSM ER, patches, and oral solutions included
    Methylphenidate HCl ER 10/20 mg QL example
    Methylphenidate HCl ER (10 & 20 mg) QL270 tabs every 75 days (example for certain ER strengths)
    ContextListed under methylphenidate ER entries with PA and age >=19 requirement
    Related QLsOther ER strengths show 180 or 90 tabs per 75 days depending on strength
    Methylphenidate ER (18/27/36 mg OSM) quantity limit
    Methylphenidate ER (18/27/36 mg OSM) QL180 tabs every 75 days (common for mid‑range ER/OSM strengths)
    PA requirementPA required for age >=19 noted for these formulations
    Alternate QLsHigher/lower strengths may have 270 or 90 tab limits per 75 days as listed
    Higher‑strength methylphenidate QL examples
    Higher‑strength methylphenidate (OSM/ER) QL90 tabs/caps every 75 days for higher strengths
    ApplicationApplies to listed higher‑strength OSM/ER formulations and patches
    PA/age notePA required for age >=19 for these higher strength entries
    OTEZLA (apremilast) quantity limits
    OTEZLA QLsExamples include 55 tabs every 28 days; 41 tabs every 28 days; or 2 tabs every 1 day depending on formulation
    SP/PAOTEZLA entries include SP and PA in addition to QL
    Preferred indicationsFormulary notes OTEZLA as preferred for Psoriasis and Psoriatic Arthritis where indicated
    RINVOQ 45 mg ER quantity limit
    RINVOQ 45 mg ER QL84 tabs every 84 days
    SP/PARINVOQ entries include SP and PA and QL as shown
    IndicationsPreferred for certain autoimmune indications as listed in formulary entries
    Butalbital‑containing product quantity limit
    Butalbital‑containing products QL48 tabs or caps every 25 days
    Age noteSome butalbital‑containing entries are marked not available under age 12
    Formulary useListed under Analgesic combinations with QL enforcement
    Aspirin 81 mg quantity limit
    Aspirin 81 mg QL100 tabs every 30 days
    Special coverage$0 copay for members capable of pregnancy age 12‑59 at risk for preeclampsia; otherwise not covered
    Formulary tierAspirin 81 mg entries shown as PV (preventive) where applicable
    Butalbital‑Acetaminophen quantity limit
    Butalbital‑Acetaminophen QL48 tabs every 25 days (example entries)
    Related formulationsIncludes butalbital‑acetaminophen and butalbital‑acetaminophen‑caffeine variants with same QL
    Age restrictionSome combination products are not available under age 12
    Tramadol oral solution quantity limit
    Tramadol oral solution QL1800 mL every 25 days (tramadol HCl oral solution 5 mg/mL example)
    Tramadol tablets QL180 tabs every 25 days for tramadol 50 mg IR example
    Age/initial limitsSubject to initial 7‑day limit; initial 3‑day limit under age 19; not available under age 12 for some forms
    Tramadol tablets (IR) quantity limit
    Tramadol tablets (IR) QL180 tabs every 25 days
    Initial‑fillSubject to initial 7‑day limit; initial 3‑day limit under age 19 where noted
    Pediatric exclusionSome tramadol formulations not available under age 12
    Oxycodone 5 mg quantity limit
    Oxycodone 5 mg QL180 tabs every 25 days
    Liquid QL900 mL every 25 days for oxycodone solutions example
    Initial‑fill limitsSubject to initial 7‑day limit; initial 3‑day limit under age 19 where indicated
    Hydromorphone liquid quantity limit
    Hydromorphone liquid QL600 mL every 25 days
    Tablet QLsExamples include 180 tabs/25 days, 150 tabs/25 days, 60 tabs/25 days depending on strength
    Initial‑fillSubject to initial 7‑day limit; initial 3‑day limit under age 19 for many formulations
    Tramadol HCl oral solution (5 mg/mL) QL
    Tramadol HCl oral solution (5 mg/mL) QL1800 mL every 25 days
    ApplicabilityMatches tramadol solution entries in formulary with PA and QL
    Initial‑fillSubject to initial limits as listed (7‑day adult; 3‑day if <=19)
    Oxycodone/acetaminophen 5‑325 mg quantity limit
    Oxycodone/acetaminophen 5‑325 mg QL360 tabs every 25 days
    ST/PA flagsMany oxycodone/acetaminophen strengths show ST and/or PA** with initial fill limits
    Provider actionPrescriptions exceeding QL require PA with medical necessity documentation
    BELBUCA films quantity limit
    BELBUCA films QL60 films every 25 days
    ST/PABELBUCA is listed with ST and PA** for many strengths; higher strengths require PA
    QL enforcementQuantity limit applies per 25‑day interval as listed
    Hydrocodone‑acetaminophen solution quantity limit
    Hydrocodone‑acetaminophen solution QL2700 mL every 25 days
    Initial‑fill noteIf age 19 or younger, subject to initial 3‑day limit where specified
    PA/QL enforcementPA required for many solution formulations when QL or age rules apply
    Anxiolytics / benzodiazepines quantity limits
    Anxiolytics/benzodiazepines QL examplesExamples include 150 tabs every 25 days; 360 caps every 25 days; 90 tabs every 25 days for some ER strengths
    Clonazepam QLClonazepam ODT and tablet entries show QL = 300 tabs every 25 days
    EnforcementPrescriptions exceeding QL require prior authorization and may be denied
    Diazepam concentrates / solutions quantity limits
    Diazepam concentrate/solution QLs240 mL every 25 days (concentrate); 1200 mL every 25 days (oral solution)
    Formulary placementThese liquid formulations are listed with specific QLs to limit supply per interval
    Provider actionRequests above QL require PA with justification
    Ipratropium bromide inhalation solution quantity limit
    Ipratropium inhalation solution QL720 mL every 75 days
    SPIRIVA QLsSPIRIVA caps: 90 caps every 75 days; SPIRIVA RESP AER: 3 inhalers every 75 days (or 720 mL for solutions)
    ContextMany anticholinergic bronchodilators have QLs expressed per 75 days
    SPIRIVA capsule / RESP AER quantity limits
    SPIRIVA caps QL90 caps every 75 days (or 720 mL every 75 days for solution formulations)
    Alternate form QLSPIRIVA RESP AER entries show 3 inhalers every 75 days for aerosol formulations
    MO flagMany SPIRIVA entries include MO for maintenance oversight
    YUPELRI (revefenacin) quantity limit
    YUPELRI QL270 mL every 75 days for YUPELRI SOL 175/3 mL (revefenacin)
    MO noteEntry lists MO along with the QL for maintenance management
    Formulary contextApplies to listed revefenacin formulation in respiratory section
    Mometasone furoate and steroid inhalant quantity limits
    Mometasone/inhalant QLs3 inhalers every 75 days or 9 inhalers every 75 days depending on product
    Albuterol examplesAlbuterol entries include QL examples such as 9 inhalers every 75 days or 180 mL every 75 days
    EnforcementQuantity limits enforced per 75‑day interval; PA required for exceptions
    Albuterol and nebulizer solution quantity limits
    Albuterol/nebulizer QLsExamples: 9 inhalers every 75 days; 180 mL every 75 days; 1125 mL every 75 days
    Levalbuterol QLsLevalbuterol solutions: 900 mL every 75 days or 270 mL for concentrated forms
    Combination inhalersTRELEGY/STIOLTO/STRIVERDI commonly limited to 3 inhalers every 75 days
    Levalbuterol solution quantity limits
    Levalbuterol QLs900 mL every 75 days (common); concentrated forms 270 mL every 75 days
    Inhaler equivalentsSome entries express limits in inhalers (e.g., 6 inhalers every 75 days) or mL depending on formulation
    MO flagMO used for maintenance management of nebulized/respiratory products
    Combination inhalers quantity limit
    Combination inhalers QL3 inhalers every 75 days (TRELEGY, STIOLTO, STRIVERDI and similar products)
    ApplicabilityApplies to many branded combination inhalers listed in the formulary respiratory section
    MO noteEntries commonly include MO for managed maintenance coverage
    STIOLTO / STRIVERDI / TRELEGY quantity limit
    STIOLTO/STRIVERDI/TRELEGY QL3 inhalers every 75 days
    Coverage requirementListed with QL and MO as coverage requirement codes
    Provider implicationPrescriptions exceeding 3 inhalers/75 days require PA or justification
    Clonazepam quantity limit
    Clonazepam QL300 tabs every 25 days (applies to ODT and tablet formulations)
    Formulary flagClonazepam entries show MO with QL enforcement
    EnforcementRequests above QL require PA/documentation and risk denial if unsupported
    ZURZUVAE (zuranolone) quantity limits
    ZURZUVAE (zuranolone) 20/25 mg QL2 caps per day (i.e., QL: 2 caps every 1 day)
    ZURZUVAE 30 mg QL1 cap per day (i.e., QL: 1 cap every 1 day)
    Coverage flagsZURZUVAE entries include SP and PA in addition to the QL — specialty pharmacy routing required
    ZURZUVAE 30 mg quantity limit
    ZURZUVAE 30 mg QL1 cap every 1 day
    SP/PASpecialty pharmacy and prior authorization required for Zurzuvæ formulations
    Provider documentationPA requests should include justification consistent with the QL per strength

    Dispensing Sites and Specialty Pharmacy Routing

    Billing Rule

    Use network retail, specialty, or mail order pharmacy for coverage

    Outpatient prescription drugs are covered only when dispensed through network retail, specialty, or mail‑order pharmacies; specialty drugs must be filled by the Sharp Health Plan specialty network pharmacy (CVS Specialty) and are limited to 30‑day supply per fill.

    • Specialty fills: route via CVS Specialty; mail order for maintenance drugs via CVS Caremark (90‑day eligible).
    Billing Rule

    Specialty Pharmacy requirement and 30‑day supply limit

    Specialty drugs must be dispensed through the Sharp Health Plan specialty network pharmacy (CVS Specialty) and are limited to a 30‑day supply per fill; ensure specialty routing for SP‑flagged products.

    • Enroll at CVSspecialty.com for specialty drug fulfillment; SP entries also often require PA and QL.

    Formulary Terms and Abbreviations

    Formulary terms and symbols
    Formulary terms includedDefinitions provided: PA = Prior Authorization; QL = Quantity Limit; ST = Step Therapy; MO = Mail Order; SP = Specialty; OAC = Oral Anti‑Cancer
    Where to find detailsSee Definitions and 'What is...' sections in the Formulary for symbol meanings and processes
    PA timelinesPA determinations: 72 hours for non‑urgent requests; 24 hours for urgent/exigent requests
    Prior Authorization and related definitions
    Prior Authorization (PA) definitionPA is Sharp Health Plan's requirement that the enrollee or prescribing provider obtain authorization before coverage; PA is granted when the drug is Medically Necessary
    PA** meaningPA** indicates prior authorization required if Step Therapy criteria have not been met
    Exception RequestAn Exception Request may be submitted for nonformulary drugs when medically necessary; approved exceptions result in coverage

    Policy Background and Scope

    The Formulary lists FDA‑approved outpatient prescription drugs covered under Sharp Health Plan and clarifies the pharmacy outpatient benefit versus the Medical Benefit. The Pharmacy & Therapeutics Committee evaluates clinical effectiveness, safety, and value in maintaining the Formulary. Members and providers may request a Formulary Exception when a nonformulary medication is determined to be Medically Necessary.